Photocure Q2 2025 presentation: Record revenue growth amid strategic expansion

Photocure ASA reported record Q2 2025 product revenue of NOK 135.6 million, an 11% year-over-year increase, signaling a strong rebound from Q1 and demonstrating robust growth across North America and Europe. The company's performance is driven by expanding U.S. market penetration and strategic initiatives, including its ForTec mobile Blue Light Cystoscopy (BLC) partnership and a significant collaboration with Richard Wolf to develop a next-generation flexible BLC scope for a $1.3 billion global market. With a strong balance sheet and maintained 2025 guidance for 7-11% product revenue growth, Photocure appears well-positioned for continued momentum, anticipating minimal impact from potential U.S. pharmaceutical tariffs.

Analysis

Photocure ASA has demonstrated a significant operational turnaround in its Q2 2025 results, posting a record product revenue of NOK 135.6 million, an 11% year-over-year increase. This performance marks a strong rebound from a challenging Q1 and is underpinned by robust execution in key markets. North American revenue grew 14%, supported by a 24% increase in active U.S. accounts to 359, while European operations expanded by 8%. The company’s focus on operating leverage is evident, with EBITDA reported at NOK 14.8 million and the contribution margin from North America more than doubling compared to Q2 2024. Strategically, Photocure is advancing key growth initiatives, including its ForTec mobile Blue Light Cystoscopy (BLC) partnership in the U.S. and a crucial partnership with Richard Wolf to develop a next-generation flexible cystoscope, targeting a $1.3 billion global market and addressing a previous 71% decline in U.S. flexible kit sales. The company maintains a strong financial position with NOK 239.1 million in cash, no term debt, and a recently completed share buy-back program. With full-year 2025 guidance reaffirmed for 7-11% product revenue growth and improving EBITDA, Photocure appears well-capitalized to execute its expansion strategy.

Key Decisions for Investors

• Given the strong rebound in Q2 revenue and reaffirmed full-year guidance, investors should view the Q1 performance as an anomaly and re-evaluate the company based on its demonstrated growth trajectory and operational execution.
• The strategic partnership with Richard Wolf to develop a next-generation flexible BLC scope is a critical long-term catalyst; its progress should be monitored closely as it directly addresses a prior product weakness and targets a substantial new market.
• The company's robust balance sheet, lack of debt, and recent share buy-back signal strong management confidence, providing a solid foundation that may mitigate risk and support continued investment in its high-growth initiatives.